首页> 外文期刊>Journal of cellular and molecular medicine. >Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs‐mediated CD8+ T cell responses
【24h】

Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs‐mediated CD8+ T cell responses

机译:间充质干细胞通过抑制CD103 + DC介导的CD8 + T细胞应答来缓解大鼠糖尿病肾病

获取原文
           

摘要

Diabetic nephropathy (DN) as a kind of serious microvascular complication of Diabetes Mellitus (DM) usually causes the end‐stage of renal disease (ESRD). Studies have demonstrated that CD103 + dendritic cells (DCs) exhibited a renal pathogenic effect in murine chronic kidney disease (CKD). Mesenchymal stem cells (MSCs) can alleviate DN and suppress the DCs maturation. To explore the role of CD103 + DCs and the potential mechanisms underlying MSCs‐mediated protective effects in DN, we used bone marrow MSCs (BM‐MSCs) to treat DN rats. MSCs transplantation considerably recovered kidney function and diminished renal injury, fibrosis and the population of renal CD103 + DCs in DN rat. The MSCs‐treated DN rats had decreased mRNA expression levels of interleukin ( IL ) 1β , IL6 , tumour necrosis factor alpha ( TNF‐α ), monocyte chemotactic protein 1 ( MCP‐1 ) and reduced CD8 T cell infiltration in the kidney. MSCs significantly down‐regulated the genes expression of transcription factors (Basic leucine zipper transcriptional factor ATF‐like 3, Batf3 and DNA‐binding protein inhibitor ID‐2, Id2 ) and FMS‐like tyrosine kinase‐3 ( Flt3 ) which are necessary for CD103 + DCs development. The protective effect of MSCs may be partly related to their immunosuppression of CD8 + T cell proliferation and activation mediated by CD103 + DCs in the kidney of DN rats.
机译:糖尿病肾病(DN)作为糖尿病(DM)的一种严重的微血管并发症通常会导致肾病的终末期(ESRD)。研究表明CD103 +树突细胞(DCS)在鼠慢性肾病(CKD)中表现出肾病作用。间充质干细胞(MSCs)可以缓解DN并抑制DCS成熟。为了探讨CD103 + DC的作用以及DN中MSC介导的保护作用的潜在机制,我们使用骨髓MSCs(BM-MSCs)治疗DN大鼠。 MSCs移植显着回收了肾功能,肾损伤,纤维化和DN大鼠肾CD103 + DCs的群体减少。 MSCS处理的DN大鼠的白细胞介素(IL)1β,IL6,肿瘤坏死因子α(TNF-α),单核细胞趋化蛋白1(MCP-1)的mRNA表达水平降低,并降低了肾脏中的CD8 T细胞浸润。 MSCs显着下调转录因子的基因(基本亮氨酸拉链转录因子ATF样3,BATF3和DNA结合蛋白抑制剂ID-2,ID2)和FMS样酪氨酸激酶-3(FLT3) CD103 + DCS开发。 MSCs的保护作用可以与其在DN大鼠肾脏肾脏中CD8 + T细胞增殖和活化的免疫抑制部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号